Caeregen Therapeutics co-Founder Dr. Michael T. Trese Honored at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting

Caeregen Therapeutics co-Founder Dr. Michael T. Trese Honored at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting

2021 Laureate Award Recognizes Exceptional Contributions in Overcoming Vision Loss

November 11, 2021, Rochester, MI and New Orleans, LA – Caeregen Therapeutics, LLC, a Michigan-based, regenerative medicine therapeutics company, today announced that company co-founder Dr. Michael T. Trese, received the prestigious Laureate Award from the American Academy of Ophthalmology (AAO) at the society’s annual conference.

The AAO’s Laureate Award, the Academy’s single highest honor, is awarded to ophthalmologists who distinguish themselves and the profession by making exceptional scientific contributions toward preventing blindness and restoring sight worldwide. As the 2021 Laureate Recognition Award Recipient, the AAO honored Dr. Trese’s extraordinary contributions over decades of dedicated research and clinical practice.  Dr. Trese’s is a Clinical Professor of Biomedical Sciences at The Eye Research Institute of Oakland University, Chief of Pediatric and Adult Vitreoretinal Surgery at William Beaumont Hospital and Clinical Associate Professor (emeritus) at Wayne State University School of Medicine.  

“It is an honor to be recognized by the Academy’s Board of Trustees from among the many distinguished, accomplished and deserving colleagues I work with and have known over my career” said Dr. Trese.  “The immense need of patients confronting progressive vision loss drives my continuing passion for the pursuit of sight restoring breakthroughs” added Dr. Trese. 

“In the course of his considerable contributions to advancing research and transforming clinical practice for treatment and prevention of vision loss, Dr. Trese has trained and inspired generations of retina specialists” said Dr. Antonio Capone, Jr., co-founder of Caeregen and Professor of Ophthalmology at Oakland University William Beaumont School of Medicine. “Dr. Trese’s boundless energy continues to drive discoveries to overcome retinal diseases and usher in regenerative medicine therapeutics to help all patients.”  

Caeregen joins the AAO in honoring Dr. Trese’s outstanding contributions and tireless pursuit of the most innovative research on behalf of patients worldwide. 


About Caeregen
Caeregen Therapeutics, LLC, based in Rochester, MI with offices in Chapel Hill, N.C., is a regenerative medicines company developing therapeutics for neurosensory diseases.  By exploiting biological pathways and signaling related to cellular and organ development, Caeregen is focused on advancing targeted therapies with the ability to repair, restore and protect neurosensory tissues affected by inherited or acquired diseases.  Caeregen is currently developing Noregen, a unique, novel, recombinant protein mimetic of human norrin-derived growth factor for the potential treatment of retinal-related vision loss.  For more information, please visit